Resultados e implicaciones del estudio ROCKET

2010, Once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study, Am Heart J, 159, 340, 10.1016/j.ahj.2009.11.025 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Granger, 2011, for the ARISTOTLE study Committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 European Medicines Agency. Xarelto, Rivaroxaban in atrial fibrillation approval. Sep 22, 2011. Disponible en: http://www.ema.europa.eu US Food and Drug Administration Nov 4, 2011. Xarelto, Rivaroxaban approval. Disponible en: http://www.fda.gov Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 2010, Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study, Am Heart J, 159, 340, 10.1016/j.ahj.2009.11.025